Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionBispecific antibody which binds VEGF-A and angiopoietin (Ang)-2
Molecular Target Vascular endothelial growth factor A (VEGF-A) ; Angiopoietin 2 (ANG2) (ANGPT2)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today